- Home
- LNTH vs NIO Comparison
LNTH vs NIO Comparison
Compare LNTH & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | NIO |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 12.8B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LNTH | NIO |
|---|---|---|
| Price | $68.80 | $4.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $78.00 | $6.73 |
| AVG Volume (30 Days) | 1.1M | ★ 40.5M |
| Earning Date | 02-25-2026 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | $1,525,933,000.00 | ★ $10,189,444,895.00 |
| Revenue This Year | $0.01 | $33.27 |
| Revenue Next Year | $0.52 | $50.24 |
| P/E Ratio | $29.12 | ★ N/A |
| Revenue Growth | 1.95 | ★ 14.90 |
| 52 Week Low | $47.25 | $3.02 |
| 52 Week High | $111.29 | $8.02 |
Technical Indicators
Market Signals| Indicator | LNTH | NIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 39.40 |
| Support Level | $66.36 | $4.74 |
| Resistance Level | $67.45 | $5.04 |
| Average True Range (ATR) | 1.66 | 0.19 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 80.18 | 7.62 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.